MA55380A - Dérivé hétéroaryle, son procédé de production et composition pharmaceutique le comprenant en tant que constituant efficace - Google Patents

Dérivé hétéroaryle, son procédé de production et composition pharmaceutique le comprenant en tant que constituant efficace

Info

Publication number
MA55380A
MA55380A MA055380A MA55380A MA55380A MA 55380 A MA55380 A MA 55380A MA 055380 A MA055380 A MA 055380A MA 55380 A MA55380 A MA 55380A MA 55380 A MA55380 A MA 55380A
Authority
MA
Morocco
Prior art keywords
production
pharmaceutical composition
effective constituent
heteroaryl derivative
heteroaryl
Prior art date
Application number
MA055380A
Other languages
English (en)
Inventor
Hwan Geun Choi
Ah Reum Han
Dong Keun Hwang
Ju Hee Kang
Se In Kang
Da Eun Kim
Hwan Kim
Nam Doo Kim
Seung Su Kim
Eun Hwa Ko
Yi Kyung Ko
Sun Hwa Lee
Youn Ho Lee
Min Seok Ryu
Ji Yoon Seok
Jung Beom Son
Original Assignee
B2Sbio Inc
Voronoi Inc
Voronoibio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B2Sbio Inc, Voronoi Inc, Voronoibio Inc filed Critical B2Sbio Inc
Publication of MA55380A publication Critical patent/MA55380A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055380A 2019-03-19 2020-03-19 Dérivé hétéroaryle, son procédé de production et composition pharmaceutique le comprenant en tant que constituant efficace MA55380A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190031269 2019-03-19
KR20190134472 2019-10-28

Publications (1)

Publication Number Publication Date
MA55380A true MA55380A (fr) 2022-01-26

Family

ID=72521153

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055380A MA55380A (fr) 2019-03-19 2020-03-19 Dérivé hétéroaryle, son procédé de production et composition pharmaceutique le comprenant en tant que constituant efficace

Country Status (22)

Country Link
US (2) US12152021B2 (fr)
EP (2) EP3943491B1 (fr)
JP (2) JP7109013B2 (fr)
KR (2) KR102318875B1 (fr)
CN (3) CN114605400B (fr)
AU (2) AU2020240382B2 (fr)
BR (1) BR112021018704B1 (fr)
CA (1) CA3134261A1 (fr)
DK (1) DK3943491T3 (fr)
ES (1) ES3036467T3 (fr)
FI (1) FI3943491T3 (fr)
HU (1) HUE073283T2 (fr)
IL (2) IL299831B2 (fr)
MA (1) MA55380A (fr)
MX (1) MX2021011160A (fr)
NZ (1) NZ781366A (fr)
PL (1) PL3943491T3 (fr)
PT (1) PT3943491T (fr)
SG (1) SG11202110376XA (fr)
SI (1) SI3943491T1 (fr)
WO (1) WO2020190119A1 (fr)
ZA (1) ZA202107889B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
EP3943491B1 (fr) * 2019-03-19 2025-06-18 Voronoi Inc. Dérivé hétéroaryle, son procédé de production et composition pharmaceutique le comprenant en tant que constituant efficace
TW202227425A (zh) * 2020-09-18 2022-07-16 南韓商沃若諾伊生物公司 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物
KR20220085735A (ko) * 2020-12-14 2022-06-22 보로노이바이오 주식회사 아이소옥사졸리딘 유도체 화합물 및 이의 용도
US12037346B2 (en) 2021-04-13 2024-07-16 Nuvalent, Inc. Amino-substituted heteroaryls for treating cancers with EGFR mutations
CN117255792A (zh) * 2021-05-07 2023-12-19 沃若诺伊公司 杂芳基衍生物、其制备方法以及包括其作为活性成分的药物组合物
AU2022271388A1 (en) 2021-05-17 2022-12-01 Voronoi Inc. Heteroaryl derivative compounds, and uses thereof
KR102563834B1 (ko) * 2021-06-28 2023-08-04 순천대학교 산학협력단 세포자멸사를 유도하는 신규한 화합물 및 이를 포함하는 항암용 조성물
CN117430600A (zh) * 2022-07-20 2024-01-23 上海和誉生物医药科技有限公司 一种选择性egfr抑制剂及其制备方法和在药学上的应用
JP2024022011A (ja) 2022-08-05 2024-02-16 三菱マテリアル株式会社 切削工具
JP2025540560A (ja) * 2022-11-03 2025-12-16 ボロノイ インコーポレイテッド Ｅｇｆｒ阻害剤のフマル酸塩、酒石酸塩、リンゴ酸塩、及びクエン酸塩
JP2025538076A (ja) * 2022-11-03 2025-11-26 オリック ファーマシューティカルズ， インコーポレイテッド Ｅｇｆｒ阻害剤のマロン酸塩及びグリコール酸塩
EP4619403A1 (fr) * 2022-11-15 2025-09-24 Voronoi, Inc. Composé dérivé hétéroaryle et ses utilisations
MX2025012495A (es) 2023-05-05 2026-02-03 Oric Pharmaceuticals Inc Inhibidor del receptor del factor de crecimiento epidérmico (egfr) para tratamiento de cánceres con mutaciones atípicas del factor de crecimiento epidérmico

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE419239T1 (de) 2000-10-20 2009-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von 4-phenoxy chinolin derivaten
EP1678147B1 (fr) 2003-09-15 2012-08-08 Lead Discovery Center GmbH Derives d'aminopyrimidine a disubstitution 4,6 actifs sur le plan pharmaceutique en tant que modulateurs des proteine kinases
EP1901747A2 (fr) 2005-05-25 2008-03-26 Ingenium Pharmaceuticals AG Inhibiteurs du cdk bases sur des pyrimidines destines au traitement de la douleur
TW200804364A (en) 2006-02-22 2008-01-16 Boehringer Ingelheim Int New compounds
CA2681250A1 (fr) 2007-03-20 2008-09-25 Smithkline Beecham Corporation Composes chimiques
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
JP2011102241A (ja) 2008-03-04 2011-05-26 Dainippon Sumitomo Pharma Co Ltd 新規１−アミノカルボニルピペリジン誘導体
CA2771190C (fr) 2009-08-17 2020-01-21 Memorial Sloan-Kettering Cancer Center Composes de liaison a une proteine de choc thermique, compositions et procedes pour les fabriquer et les utiliser
KR101401664B1 (ko) 2011-11-15 2014-06-11 중앙대학교 산학협력단 신경줄기세포 분화조절제용 신규 피리미딘-2,4-디아민 유도체 및 이의 의학적 용도
NZ627113A (en) 2012-01-20 2016-07-29 Genosco Substituted pyrimidine compounds and their use as syk inhibitors
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
EP2903972B1 (fr) 2012-10-04 2019-12-04 University of Utah Research Foundation Analogues de n-(3-(pyrimidin-4-yl)phényl) substitué utilisés en tant qu'inhibiteurs de récepteur tyrosine kinase btk
EP2769722A1 (fr) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Composés utilisés pour inhiber un assemblage de capside du VIH
WO2014141104A1 (fr) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
EP3037424B1 (fr) 2013-08-22 2017-11-08 Taiho Pharmaceutical Co., Ltd. Nouveau composé substitué par une quinoline
RU2019131017A (ru) 2013-10-21 2019-11-25 Мерк Патент Гмбх Соединения гетероарила в качестве ингибиторов btk и их применение
KR20150047855A (ko) 2013-10-25 2015-05-06 한미약품 주식회사 단백질 카이네이즈 억제 효과를 갖는 2-사이아노-아크릴아마이드 유도체
CN106687457B (zh) 2014-05-13 2020-01-10 阿里亚德医药股份有限公司 用于激酶抑制的杂芳基化合物
PE20170268A1 (es) 2014-06-19 2017-04-21 Ariad Pharma Inc Compuestos de heteroarilo para la inhibicion de cinasa
RU2702631C2 (ru) * 2014-10-11 2019-10-09 Шанхай Хэнсох Биомедикал Ко., Лтд. Ингибитор egfr и его получение и применение
MX2017003181A (es) * 2014-10-13 2017-07-20 Yuhan Corp Compuestos y composiciones para modular actividades de quinasa de mutante de receptor del factor de crecimiento epidermico.
US10059689B2 (en) 2014-10-14 2018-08-28 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
US10266517B2 (en) 2014-12-23 2019-04-23 Dana-Farber Cancer Institute, Inc. Pyrimidines as EGFR inhibitors and methods of treating disorders
JP6970081B2 (ja) 2015-07-16 2021-11-24 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 アニリンピリミジン誘導体及びその使用
CN106478607B (zh) 2015-08-28 2019-05-24 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
US10377747B2 (en) 2015-08-31 2019-08-13 Wuxi Shuangliang Biotechnology Co., Ltd. 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof
CN108602809B (zh) 2015-12-04 2022-09-30 戴纳立制药公司 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂
EP3399968B8 (fr) 2016-01-07 2021-12-01 Xuanzhu Biopharmaceutical Co., Ltd. Inhibiteurs sélectifs de mutants cliniquement importants de la tyrosine kinase de l'egfr
WO2017156527A1 (fr) 2016-03-11 2017-09-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibiteurs des kinases aurora et des janus kinases pour la prévention de la maladie du greffon contre l'hôte
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
TWI808977B (zh) 2017-06-13 2023-07-21 大陸商北京浦潤奧生物科技有限責任公司 胺基嘧啶類化合物及其製備方法和用途
EP3648753A4 (fr) * 2017-07-05 2021-03-17 CS Pharmatech Limited Inhibiteurs sélectifs de mutants cliniquement importants de la tyrosine kinase de l'egfr
US11339157B1 (en) 2017-10-24 2022-05-24 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
TWI798334B (zh) 2018-01-31 2023-04-11 大陸商迪哲（江蘇）醫藥股份有限公司 Ｅｒｂｂ／ｂｔｋ抑制劑
CN108191774B (zh) 2018-01-31 2022-05-24 中国药科大学 一类杂环化合物、其制备方法和用途
KR102782739B1 (ko) 2018-03-13 2025-03-20 보로노이 주식회사 2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2019177374A1 (fr) 2018-03-13 2019-09-19 포로노이바이오 주식회사 Dérivé de pyrimidine substitué en positions 2, 4 et 5, son procédé de préparation, et composition pharmaceutique le comprenant en tant que principe actif pour la prévention ou le traitement du cancer ou d'une maladie inflammatoire
KR20200144579A (ko) 2018-05-14 2020-12-29 어리어드 파마슈티칼스, 인코포레이티드 피리미딘 유도체의 약학 염 및 장애의 치료 방법
CN109280048A (zh) 2018-11-16 2019-01-29 江西科技师范大学 一种含取代苯基丙烯酰胺结构的嘧啶类化合物及其应用
CN109608394A (zh) 2018-12-03 2019-04-12 湖南大学 氮杂芳胺类化合物的合成方法和氮杂芳胺类化合物
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
EP3943491B1 (fr) * 2019-03-19 2025-06-18 Voronoi Inc. Dérivé hétéroaryle, son procédé de production et composition pharmaceutique le comprenant en tant que constituant efficace

Also Published As

Publication number Publication date
SI3943491T1 (sl) 2025-08-29
IL286471A (en) 2021-12-01
KR102318875B1 (ko) 2021-11-01
CN113993866B (zh) 2022-10-28
EP3943491A1 (fr) 2022-01-26
IL299831B2 (en) 2025-12-01
JP2022522250A (ja) 2022-04-14
EP3943491B1 (fr) 2025-06-18
FI3943491T3 (fi) 2025-07-31
JP2022125283A (ja) 2022-08-26
EP4631507A2 (fr) 2025-10-15
CN114605400A (zh) 2022-06-10
ES3036467T3 (en) 2025-09-19
DK3943491T3 (da) 2025-07-14
WO2020190119A1 (fr) 2020-09-24
CN115838369A (zh) 2023-03-24
BR112021018704A2 (fr) 2021-11-23
CA3134261A1 (fr) 2020-09-24
AU2020240382A1 (en) 2021-11-11
EP4631507A3 (fr) 2025-12-24
IL286471B1 (en) 2023-04-01
IL286471B2 (en) 2023-08-01
JP7394298B2 (ja) 2023-12-08
IL299831B1 (en) 2025-08-01
CN114605400B (zh) 2024-09-10
CN113993866A (zh) 2022-01-28
US11466000B2 (en) 2022-10-11
PL3943491T3 (pl) 2025-11-17
US20220073505A1 (en) 2022-03-10
KR20210130123A (ko) 2021-10-29
IL299831A (en) 2023-03-01
EP3943491A4 (fr) 2022-11-23
BR112021018704B1 (pt) 2023-01-10
KR102564533B1 (ko) 2023-08-08
JP7109013B2 (ja) 2022-07-29
HUE073283T2 (hu) 2026-01-28
MX2021011160A (es) 2022-02-10
US12152021B2 (en) 2024-11-26
AU2020240382B2 (en) 2022-08-25
KR20200111644A (ko) 2020-09-29
SG11202110376XA (en) 2021-10-28
ZA202107889B (en) 2024-02-28
PT3943491T (pt) 2025-07-28
AU2022211789A1 (en) 2022-08-25
NZ781366A (en) 2022-08-26
AU2022211789B2 (en) 2024-06-27
US20220162203A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
EP3943491A4 (fr) Dérivé hétéroaryle, son procédé de production et composition pharmaceutique le comprenant en tant que constituant efficace
EP3750887A4 (fr) Dérivé de biaryle, son procédé de préparation, et son application pharmaceutique
EP3978496A4 (fr) Dérivé de cycle inhibiteur de btk, son procédé de préparation et son application pharmaceutique
EP3450423A4 (fr) Dérivé de benzylphényl éther, son procédé de préparation et composition pharmaceutique et utilisations associées
CY1122994T1 (el) Μεθοδος καθαρισμου κανναβινοειλων, συνθεσεων και kit αυτων
EP3459940A4 (fr) Dérivé de 5-aminopyrazole carboxamide en tant qu'inhibiteur de la btk, son procédé de préparation et composition pharmaceutique associée
EP3357491A4 (fr) Composition pharmaceutique contenant un médicament anionique, et son procédé de préparation
EP3909982A4 (fr) Anticorps cd73, son procédé de préparation et son application
EP3486242A4 (fr) Dérivé d'oxopicolinamide, son procédé de préparation et son utilisation pharmaceutique
EP4079734A4 (fr) Dérivé de triazolopyridazine, son procédé de préparation, composition pharmaceutique associée et utilisation correspondante
EP3398939A4 (fr) Dérivé d'acrylanilide, son procédé de préparation et ses applications en pharmacie
EP4056571A4 (fr) Dérivé de dihydroimidazopyrimidone tricyclique, son procédé de préparation, composition pharmaceutique et son utilisation
EP3744316A4 (fr) Composition pharmaceutique ophtalmique, son procédé de préparation et son application
BR112017019287A2 (pt) composto, composição farmaceuticamente aceitável, método de tratamento de câncer, processo para preparar o composto da fórmula i, método para tratar câncer, e kit
EP4056177A4 (fr) Préparation de nanomicelles de cannabinoïde et son procédé de préparation
EP3805231A4 (fr) Inhibiteur contenant un dérivé tricyclique, son procédé de préparation et son application
EP3399029A4 (fr) Virus mutant, son procédé de préparation et son application
EP3352006A4 (fr) Composition d'étanchéité, panneau d'affichage et son procédé de préparation, et appareil d'affichage
EP3498716A4 (fr) Composé thiénopyrimidine, son procédé de préparation, composition pharmaceutique et applications associées
EP3466946A4 (fr) Thiophène, son procédé de fabrication, et application pharmaceutique correspondante
EP3943089A4 (fr) Formulation lyophilisée, procédé de préparation et application correspondante
EP3653202A4 (fr) Préparation pharmaceutique et son procédé de préparation
EP3398615A4 (fr) Composition pharmaceutique mucoadhésive et son procédé de préparation
EP4045534A4 (fr) Anticorps, composition pharmaceutique et procédé
EP3623503A4 (fr) Médicament protéique multispécifique et bibliothèque associée, procédé de préparation associé et application associée